78.73 0.00 (0.00%)
After hours: 4:55PM EDT
|Bid||78.15 x 100|
|Ask||79.34 x 100|
|Day's Range||78.16 - 80.20|
|52 Week Range||73.69 - 89.09|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 24, 2018|
|Forward Dividend & Yield||2.25 (2.86%)|
|1y Target Est||91.24|
Former Executive Chairman Paul Jacobs is considering a leveraged buyout, which would be incredibly expensive and face tough regulatory scrutiny.
Let's see if Eli Lilly and Company (LLY) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
As discussed earlier, Pfizer’s (PFE) revenue rose ~1% to $13.7 billion during 4Q17 driven by increased sales of its Innovative Health products. It reflects revenues for both Pfizer’s Innovative Health and Essential Health segments in 4Q17. Pfizer reported a fall of ~4% in its US sales in 4Q17, while its sales outside US markets reported a 5% revenue rise in the quarter.
Do we trade on the news out of Washington? Jim Cramer talks about Larry Kudlow and his stand on economic growth.